ECSP12011945A - Espiroindolinona-pirrolidinas - Google Patents

Espiroindolinona-pirrolidinas

Info

Publication number
ECSP12011945A
ECSP12011945A ECSP12011945A ECSP12011945A EC SP12011945 A ECSP12011945 A EC SP12011945A EC SP12011945 A ECSP12011945 A EC SP12011945A EC SP12011945 A ECSP12011945 A EC SP12011945A
Authority
EC
Ecuador
Prior art keywords
pirrolidinas
espiroindolinona
compounds
enantiomers
esters
Prior art date
Application number
Other languages
English (en)
Inventor
David Joseph Bartkovitz
Xin Jie Chu
Qingjie Ding
Nan Jiang
Zhuming Zhang
Jing Zhang
Bradford James Graves
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ECSP12011945A publication Critical patent/ECSP12011945A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Se proporcionan compuestos de la fórmulaen la que X, Y y de R1 a R8 tienen los significados aquí definidos, junto con los enantiómeros, las sales farmacéuticamente aceptables y los ésteres de los mismos. Estos compuestos son útiles como agentes anticancerosos.
ECSP12011945 2009-12-02 2012-06-01 Espiroindolinona-pirrolidinas ECSP12011945A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26579209P 2009-12-02 2009-12-02
US38805410P 2010-09-30 2010-09-30

Publications (1)

Publication Number Publication Date
ECSP12011945A true ECSP12011945A (es) 2012-07-31

Family

ID=43608656

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12011945 ECSP12011945A (es) 2009-12-02 2012-06-01 Espiroindolinona-pirrolidinas

Country Status (26)

Country Link
US (1) US8088815B2 (es)
EP (1) EP2507243B1 (es)
JP (1) JP5647262B2 (es)
KR (1) KR101418191B1 (es)
CN (1) CN102741257B (es)
AR (1) AR079226A1 (es)
AU (1) AU2010326855B2 (es)
BR (1) BR112012012872A2 (es)
CA (1) CA2781823A1 (es)
CL (1) CL2012001405A1 (es)
CO (1) CO6541606A2 (es)
CR (1) CR20120259A (es)
EC (1) ECSP12011945A (es)
ES (1) ES2543468T3 (es)
IL (1) IL220010A (es)
MA (1) MA33976B1 (es)
MX (1) MX2012006260A (es)
MY (1) MY160596A (es)
NZ (1) NZ600024A (es)
PE (1) PE20121334A1 (es)
PH (1) PH12012501029A1 (es)
RU (1) RU2571100C2 (es)
SG (1) SG181465A1 (es)
TW (1) TW201129571A (es)
WO (1) WO2011067185A1 (es)
ZA (1) ZA201204036B (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889632B2 (en) 2007-01-31 2014-11-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
EP2508531B1 (en) 2007-03-28 2016-10-19 President and Fellows of Harvard College Stitched polypeptides
CN104876938A (zh) 2009-11-12 2015-09-02 密歇根大学董事会 螺-吲哚酮mdm2拮抗剂
US20110118283A1 (en) * 2009-11-17 2011-05-19 Qingjie Ding Substituted Pyrrolidine-2-Carboxamides
US8288431B2 (en) * 2010-02-17 2012-10-16 Hoffmann-La Roche Inc. Substituted spiroindolinones
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
SI2603600T1 (sl) 2010-08-13 2019-04-30 Aileron Therapeutics, Inc. Peptidomimetični makrocikli
US20120046306A1 (en) * 2010-08-18 2012-02-23 David Joseph Bartkovitz Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists
PE20140408A1 (es) 2010-11-12 2014-04-10 Univ Michigan Derivados espiro-oxindol como antagonistas de mdm2
TR201807311T4 (tr) * 2011-03-10 2018-06-21 Daiichi Sankyo Co Ltd Dispiropirolidin derivesi.
MX346375B (es) 2011-05-11 2017-03-16 Univ Michigan Regents Antagonistas de espiro-oxindol de mdm2.
MX352672B (es) 2011-09-27 2017-12-04 Amgen Inc Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer.
TW201806968A (zh) 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
HK1205454A1 (en) 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
KR102112373B1 (ko) 2012-02-15 2020-05-18 에일러론 테라퓨틱스 인코포레이티드 펩티드모방체 마크로사이클
TWI586668B (zh) 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
WO2014071241A1 (en) 2012-11-01 2014-05-08 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
WO2014100065A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
CN103113854B (zh) * 2013-02-06 2015-11-18 青岛奥环新能源科技发展有限公司 一种移动供热用复合相变材料及其制备方法
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
WO2014134201A1 (en) 2013-02-28 2014-09-04 Amgen Inc. A benzoic acid derivative mdm2 inhibitor for the treatment of cancer
WO2014151863A1 (en) 2013-03-14 2014-09-25 Amgen Inc. Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer
MA53572A1 (fr) 2013-06-10 2021-10-29 Amgen Inc Procédés de production et formes cristallines d'un inhibiteur mdm2
CN103342672B (zh) * 2013-07-02 2015-12-23 扬州大学 取代吡咯烷-2-酮的新合成方法
AU2015247646B2 (en) 2014-04-17 2019-06-06 The Regents Of The University Of Michigan MDM2 inhibitors and therapeutic methods using the same
WO2016001376A1 (en) 2014-07-03 2016-01-07 Boehringer Ingelheim International Gmbh New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
CN105829318B (zh) * 2014-08-18 2018-10-02 哈德森生物医药有限公司 作为mdm2抑制剂的螺吡咯烷
JP6591532B2 (ja) 2014-08-21 2019-10-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ＭＤＭ２−ｐ５３阻害剤としての新しいスピロ［３Ｈ−インドール−３，２’−ピロリジン］−２（１Ｈ）−オン化合物および誘導体
BR112017005598A2 (pt) 2014-09-24 2017-12-12 Aileron Therapeutics Inc macrociclos peptidomiméticos e usos dos mesmos
JP2018503595A (ja) 2014-09-24 2018-02-08 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ペプチド模倣大環状分子およびその製剤
WO2016154058A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
RU2629750C2 (ru) * 2015-04-09 2017-09-01 Ян Андреевич Иваненков НОВЫЕ ДИСПИРО-ИНДОЛИНОНЫ, ИНГИБИТОРЫ MDM2/p53 ВЗАИМОДЕЙСТВИЯ, СПОСОБ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
US10023613B2 (en) 2015-09-10 2018-07-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of MCL-1
HUE054985T2 (hu) 2015-10-09 2021-11-29 Boehringer Ingelheim Int Spiro[3H-indol-3,2'-pirrolidin]-2(1H)-on vegyületek és számrazékok, mint MDM2-P53 inhibitorok
GB201603779D0 (en) 2016-03-04 2016-04-20 Mission Therapeutics Ltd Novel compounds
AU2017246452C1 (en) 2016-04-06 2021-06-03 The Regents Of The University Of Michigan MDM2 protein degraders
CN105949221B (zh) * 2016-05-11 2017-08-25 湖南科技大学 一种含螺吲哚‑2‑酮衍生物及其制备方法和作为抗癌药物的应用
CN109152843A (zh) 2016-05-20 2019-01-04 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
WO2018027477A1 (zh) 2016-08-08 2018-02-15 肖飞 螺环吲哚酮聚乙二醇碳酸酯类化合物和其组合物、制备方法及用途
EP3511334A1 (en) * 2018-01-16 2019-07-17 Adamed sp. z o.o. 1,2,3',5'-tetrahydro-2'h-spiro[indole-3,1'-pyrrolo[3,4-c]pyrrole]-2,3'-dione compounds as therapeutic agents activating tp53
RU2730287C1 (ru) * 2019-08-30 2020-08-21 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Новые 2',5'-диарилспиро[индол-3,3'-пирролидин]-2(1н)-оны и способ их получения
GB201919219D0 (en) 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers
JP2023539867A (ja) 2020-08-27 2023-09-20 大塚製薬株式会社 Ｍｄｍ２アンタゴニストを用いた癌治療に関するバイオマーカー
US12569564B2 (en) 2021-01-23 2026-03-10 Newave Pharmaceutical Inc. Spirocyclic MDM2 modulator and uses thereof
WO2022183006A1 (en) 2021-02-25 2022-09-01 Mayo Foundation For Medical Education And Research Compounds for programmable protein degradation and methods of use for the disease treatment
GB202103080D0 (en) 2021-03-04 2021-04-21 Otsuka Pharma Co Ltd Cancer biomarkers
CN115215872A (zh) * 2021-04-15 2022-10-21 中国科学院上海药物研究所 具有取代苯基螺[吲哚啉-3,3′-吡咯烷]结构的小分子化合物
US12398147B2 (en) 2021-05-11 2025-08-26 Enanta Pharmaceuticals, Inc. Macrocyclic spiropyrrolidine derived antiviral agents
CN113387957B (zh) * 2021-06-09 2022-08-09 江苏亚尧生物科技有限公司 螺环吲哚酮-吡咯烷碳酸酯化合物和其组合物、制备方法及用途
US12643905B2 (en) 2021-07-23 2026-06-02 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US12479854B2 (en) 2021-07-29 2025-11-25 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2023086400A1 (en) * 2021-11-12 2023-05-19 Enanta Pharmaceuticals, Inc. Novel spiropyrrolidine derived antiviral agents
US11993600B2 (en) 2021-12-08 2024-05-28 Enanta Pharmaceuticals, Inc. Saturated spirocyclics as antiviral agents
CN116283701B (zh) * 2021-12-21 2025-04-22 中国科学院上海药物研究所 具有4-(取代氨甲基)-5-新戊基-n-取代基吡咯烷-2-甲酰胺结构的化合物
CN114773327B (zh) * 2022-04-18 2023-08-18 广东优康精细化工有限公司 一种吡噻菌胺中间体的制备方法
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2759935A (en) * 1953-02-18 1956-08-21 Bristol Lab Inc Substituted 3-phenyloxindoles
US3441570A (en) * 1966-01-20 1969-04-29 Parke Davis & Co 3-tertiary aminoalkylamino-3-phenyl oxindole compounds
US3686210A (en) * 1970-01-13 1972-08-22 American Home Prod 2-acylamido-3-aryl-3h-indol-3-ol esters and related compounds
US4020179A (en) * 1975-05-15 1977-04-26 Richardson-Merrell Inc. 7-Substituted-2-indolinones
JPS55129284A (en) 1979-03-27 1980-10-06 Shionogi & Co Ltd 3-(1-imipazolyl)indolin-2-one
DE3714473A1 (de) 1987-04-30 1988-11-10 Basf Ag Kontinuierliches verfahren zur epimerisierung von zuckern, insbesondere von d-arabinose zu d-ribose
RU2084449C1 (ru) * 1994-03-02 1997-07-20 Всероссийский научный центр по безопасности биологически активных веществ 1-бензил-2-оксотриптамин гидрохлорид и его производные, обладающие гепатозащитной активностью
FR2740136B1 (fr) 1995-10-24 1998-01-09 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant
WO1998054167A1 (en) 1997-05-28 1998-12-03 Mitsubishi-Tokyo Pharmaceuticals, Inc. Indole compounds
US6511974B1 (en) * 1997-07-30 2003-01-28 Wyeth Tricyclic vasopressin agonists
EP0947511A1 (en) 1998-03-30 1999-10-06 F. Hoffmann-La Roche Ag Derivatives of phenoxy acetic acid and of phenoxymethyl tetrazole having antitumor activity
GB9819860D0 (en) 1998-09-12 1998-11-04 Zeneca Ltd Chemical compounds
JP2000191661A (ja) 1998-12-25 2000-07-11 Mitsubishi-Tokyo Pharmaceuticals Inc 環状アミド化合物
IL144977A0 (en) 1999-05-21 2002-06-30 Bristol Myers Squibb Co Pyrrolotriazine derivatives and pharmaceutical compositions containing the same
JP2003505388A (ja) * 1999-07-21 2003-02-12 アストラゼネカ・アクチエボラーグ 新規化合物
FR2827604B1 (fr) 2001-07-17 2003-09-19 Sanofi Synthelabo Nouveaux derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2- one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
JP2006508893A (ja) 2002-03-15 2006-03-16 イーライ・リリー・アンド・カンパニー ステロイドホルモン核内レセプターモジュレーターとしてのジヒドロインドール−２−オン誘導体
DE202004014849U1 (de) * 2004-09-23 2005-02-03 Trw Automotive Safety Systems Gmbh Vorrichtung zur Bestimmung eines absoluten Drehwinkels
US8030499B2 (en) 2005-01-28 2011-10-04 Taisho Pharmaceutical Co., Ltd. 1,3-dihydro-2H-indole-2-one compound and pyrrolidine-2-one compound fused with aromatic heterocycle
AU2006216780B8 (en) * 2005-02-22 2010-04-22 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and uses thereof
US7576082B2 (en) 2005-06-24 2009-08-18 Hoffman-La Roche Inc. Oxindole derivatives
US20070213341A1 (en) 2006-03-13 2007-09-13 Li Chen Spiroindolinone derivatives
US7495007B2 (en) * 2006-03-13 2009-02-24 Hoffmann-La Roche Inc. Spiroindolinone derivatives
DE602007011902D1 (de) 2006-03-13 2011-02-24 Hoffmann La Roche Spiroindolinon-derivate
WO2008005268A1 (en) 2006-06-30 2008-01-10 Schering Corporation Substituted piperidines that increase p53 activity and the uses thereof
US7737174B2 (en) * 2006-08-30 2010-06-15 The Regents Of The University Of Michigan Indole inhibitors of MDM2 and the uses thereof
CA2661354C (en) 2006-08-30 2012-12-18 The Regents Of The University Of Michigan New small molecule inhibitors of mdm2 and the uses thereof
US7638548B2 (en) 2006-11-09 2009-12-29 Hoffmann-La Roche Inc. Spiroindolinone derivatives
WO2008080822A1 (en) 2006-12-29 2008-07-10 F. Hoffmann-La Roche Ag Epimerization methodologies for recovering stereo isomers in high yield and purity
US7553833B2 (en) * 2007-05-17 2009-06-30 Hoffmann-La Roche Inc. 3,3-spiroindolinone derivatives
US7776875B2 (en) 2007-12-19 2010-08-17 Hoffman-La Roche Inc. Spiroindolinone derivatives
US8258134B2 (en) 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators
US8354444B2 (en) * 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
CA2734363C (en) * 2008-09-18 2016-10-25 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
CN104876938A (zh) * 2009-11-12 2015-09-02 密歇根大学董事会 螺-吲哚酮mdm2拮抗剂
AU2011237782A1 (en) * 2010-04-09 2012-10-25 The Regents Of The University Of Michigan Biomarkers for MDM2 inhibitors for use in treating disease

Also Published As

Publication number Publication date
NZ600024A (en) 2014-08-29
CL2012001405A1 (es) 2012-09-28
JP5647262B2 (ja) 2014-12-24
CA2781823A1 (en) 2011-06-09
IL220010A0 (en) 2012-07-31
JP2013512869A (ja) 2013-04-18
EP2507243A1 (en) 2012-10-10
AU2010326855B2 (en) 2015-10-29
BR112012012872A2 (pt) 2017-10-10
CN102741257A (zh) 2012-10-17
CO6541606A2 (es) 2012-10-16
RU2571100C2 (ru) 2015-12-20
ZA201204036B (en) 2013-02-27
KR20120101481A (ko) 2012-09-13
HK1173720A1 (en) 2013-05-24
MY160596A (en) 2017-03-15
KR101418191B1 (ko) 2014-07-09
AR079226A1 (es) 2012-01-04
US8088815B2 (en) 2012-01-03
AU2010326855A1 (en) 2012-06-21
MX2012006260A (es) 2012-06-19
WO2011067185A1 (en) 2011-06-09
SG181465A1 (en) 2012-07-30
MA33976B1 (fr) 2013-02-01
IL220010A (en) 2014-03-31
ES2543468T3 (es) 2015-08-19
CR20120259A (es) 2012-07-12
PE20121334A1 (es) 2012-10-12
EP2507243B1 (en) 2015-06-10
TW201129571A (en) 2011-09-01
PH12012501029A1 (en) 2013-01-14
RU2012125763A (ru) 2014-01-10
CN102741257B (zh) 2015-03-04
US20110130398A1 (en) 2011-06-02

Similar Documents

Publication Publication Date Title
CR20120259A (es) Espiroindolinona-pirrolidinas
CR20120410A (es) Pirrolidina-2-carboxamidas sustituidas
CO6361910A2 (es) Pirrolidina-2-carboxamidas sustituidas
ECSP13013074A (es) Nuevos derivados de piridina
MX2019010602A (es) Inhibidores de cdk.
CR20140399A (es) Pirrolidina-2-carboxamidas sustituidas
CR20120594A (es) Compuestos heteroarilo nitrogenados
CR20150250A (es) Nuevos derivados de piridina
CR20120443A (es) Derivados de (imidazopirimidina-7-il)-heteroarilamida y su uso como inhibidores de pde10a
CU24078B1 (es) Tres compuestos de sulfonamidas anilladas
CO6741154A2 (es) Compuestos de triazolopiridina
CO6630154A2 (es) Ciertas amino-piridazinas, composiciones de las mismas y métodos de uso de los mimos
CR20140525A (es) Compuestos de N-alquiltriazol como antagonistas de LPAR
MX2019011890A (es) Liberacion controlada de inmunosupresores a partir de nanoportadores sinteticos.
CO6620055A2 (es) Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos
MX2014014229A (es) Pirrolidina-2-carboxamidas sustituidas.
CR20150204A (es) Nuevos derivados de piridina
UY33427A (es) Derivados de carbamatos de hexafluoroisopropilo, su preparacion y su aplicacion en terapeutica
NI201500038A (es) Piridinonas bicíclicas novedosas
UY32553A (es) Nuevos derivados de la pirrolidinadiona espiroheterocíclicos 3-sustituidos
DK2931970T4 (da) Cellulose-afledte sammensætninger
CR20130318A (es) Nuevos compuestos de benzodioxol-piperazina
UY33179A (es) Derivados de ácido carboxílico que comprenden un anillo de oxazolopirimidina 2,5-sustituido.
UY33180A (es) Derivados de ácido carboxílico heterocíclicos que comprenden un anillo de oxazolopirimidina 2,5-sustituida.
HN2009001330A (es) Compuestos novedosos activos como antagonistas de receptore muscarinico